G
G

Gilead

交易方向

交易者脈動

技術摘要

小時

財經新聞

Wall Street Journal - Jan 19

Jan 19 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Microsoft Corp MSFT.O agreed to buy Activision Blizzard Inc ATVI.O in an all-cash deal valued at about $75 billion, using its largest acquisition by far to grab a videogame heavyweight that
A
A
G
M
V

EU drug regulator won't rule on Merck 19 pill before Christmas - source

By Emilio Parodi MILAN, Dec 17 (Reuters) - The EU drug regulator will not decide whether to approve Merck & Co's MRK.N COVID-19 pill until after Christmas, a source with knowledge of the matter said, as the region scrambles to boost its arsenal of drugs to fight the Omicron variant. But the European Medicines Agency (EMA) will rule before Christmas
G

EU regulator builds Omicron defences with approvals of Vir, Sobi drugs

* EMA approves Kineret and Xevudy for COVID-19 treatment * Kineret for adults with pneumonia, lung failure risk * Xevudy for adults, adolescents at risk of severe disease By Pushkala Aripaka and Amna Karimi Dec 16 (Reuters) - The European Union's drug regulator on Thursday approved a COVID-19 treatment from British-U.S. duo GSK GSK.L and Vir Biotec
A
G
G
P
R
R
S

Europe secures 55,000 doses of Roche-Regeneron COVID drug hope

By Francesco Guarascio and John Miller BRUSSELS, June 3 (Reuters) - The European Union has secured about 55,000 doses of a potential treatment for COVID-19 based on a cocktail of monoclonal antibodies developed by U.S. drugmaker Regeneron REGN.O and Swiss pharmaceutical giant Roche ROG.S , an EU spokesman said. The deal is the bloc's first contract
G
R
R

Inside the race to find a 19 treatment pill

By Deena Beasley LOS ANGELES, May 21 (Reuters) - In early 2020, as a new deadly coronavirus began spreading around the world, Pfizer Inc PFE.N assembled what it called a “SWAT team” of scientists and chemists to identify a potential treatment to fight COVID-19. The U.S. pharmaceutical giant, which had begun exploring a vaccine, also wanted to p
G
P
R

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明